Kymera Therapeutics to Announce First Quarter 2026 Financial Results and Host Video Conference Call

Kymera Therapeutics will announce Q1 2026 financial results on April 30, 2026, with a video conference at 8:30 a.m. ET.

Quiver AI Summary

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing oral small molecule degrader medicines for immunological diseases, will announce its financial results for the first quarter of 2026 on April 30, 2026, followed by a video conference call and webcast at 8:30 a.m. ET. Interested participants can register for the call through the company's website. Kymera is a pioneer in targeted protein degradation, working on innovative therapies that tackle previously inaccessible disease targets. Established in 2016, the company has gained recognition as one of Boston's top workplaces. Additional details about the company's science and pipeline are available on their website or social media.

Potential Positives

Kymera Therapeutics is advancing a novel class of oral small molecule degrader medicines, positioning itself as an innovator in the treatment of immunological diseases.
The company has successfully advanced its first degrader into clinical trials, demonstrating its commitment to developing effective therapies that are poised to improve patient outcomes.
Kymera is focused on building an industry-leading pipeline, which indicates potential for future growth and expansion in its therapeutic offerings.
Recognition as one of Boston’s top workplaces enhances the company’s reputation and may aid in attracting talent and investment.

Potential Negatives

The press release does not provide any financial performance metrics or anticipated results, which may raise concerns among investors about the company’s transparency or financial health.
The company’s clinical-stage status may indicate a prolonged path to profitability, potentially leading to investor apprehension regarding future financial stability.
Details on the specifics of their pipeline or upcoming studies were not disclosed, which could lead to uncertainty about the future direction and viability of their product development efforts.

FAQ

When will Kymera Therapeutics report its financial results?

Kymera Therapeutics will report its first quarter 2026 financial results on April 30, 2026.

How can I join the Kymera Therapeutics video conference?

You can join the video conference by registering via the provided link or visiting the “News and Events” section on their website.

What is the focus of Kymera Therapeutics' research?

Kymera Therapeutics focuses on developing oral small molecule degrader medicines for immunological diseases using targeted protein degradation.

What is targeted protein degradation (TPD)?

Targeted protein degradation (TPD) is a therapeutic approach that aims to eliminate disease-causing proteins inaccessible to conventional treatments.

Where can I find more information about Kymera Therapeutics?

More information about Kymera Therapeutics can be found on their official website at www.kymeratx.com.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$KYMR Insider Trading Activity

$KYMR insiders have traded $KYMR stock on the open market 94 times in the past 6 months. Of those trades, 2 have been purchases and 92 have been sales.

Here’s a breakdown of recent trading of $KYMR stock by insiders over the last 6 months:

BROS. ADVISORS LP BAKER has made 2 purchases buying 2,005,813 shares for an estimated $172,499,918 and 0 sales.
BRUCE BOOTH has made 0 purchases and 18 sales selling 246,082 shares for an estimated $22,553,582.
NELLO MAINOLFI (Chief Executive Officer) has made 0 purchases and 11 sales selling 190,000 shares for an estimated $15,796,488.
JEREMY G CHADWICK (Chief Operating Officer) has made 0 purchases and 21 sales selling 176,484 shares for an estimated $14,199,203.
JARED GOLLOB (Chief Medical Officer) has made 0 purchases and 13 sales selling 59,815 shares for an estimated $5,288,501.
PAMELA ESPOSITO has made 0 purchases and 12 sales selling 38,063 shares for an estimated $3,054,148.
BRUCE N. JACOBS (Chief Financial Officer) has made 0 purchases and 7 sales selling 12,471 shares for an estimated $1,091,230.
ELENA RIDLOFF has made 0 purchases and 3 sales selling 12,000 shares for an estimated $1,024,660.
NOAH GOODMAN (Chief Business Officer) has made 0 purchases and 5 sales selling 11,611 shares for an estimated $1,019,012.
JEFFREY W. ALBERS has made 0 purchases and 2 sales selling 5,000 shares for an estimated $448,823.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$KYMR Hedge Fund Activity

We have seen 153 institutional investors add shares of $KYMR stock to their portfolio, and 90 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

FMR LLC added 3,048,963 shares (+51.9%) to their portfolio in Q4 2025, for an estimated $237,239,811
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 2,542,550 shares (-73.6%) from their portfolio in Q4 2025, for an estimated $197,835,815
BAKER BROS. ADVISORS LP added 2,005,813 shares (+30.2%) to their portfolio in Q4 2025, for an estimated $156,072,309
AVORO CAPITAL ADVISORS LLC added 1,124,747 shares (+17.7%) to their portfolio in Q4 2025, for an estimated $87,516,564
PRICE T ROWE ASSOCIATES INC /MD/ added 1,061,957 shares (+20.8%) to their portfolio in Q4 2025, for an estimated $82,630,874
ALLIANCEBERNSTEIN L.P. added 903,296 shares (+1852.2%) to their portfolio in Q4 2025, for an estimated $70,285,461
VANGUARD GROUP INC added 845,922 shares (+15.6%) to their portfolio in Q4 2025, for an estimated $65,821,190

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$KYMR Analyst Ratings

Wall Street analysts have issued reports on $KYMR in the last several months. We have seen 10 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

BTIG issued a "Buy" rating on 02/03/2026
Stephens & Co. issued a "Overweight" rating on 12/11/2025
Mizuho issued a "Outperform" rating on 12/11/2025
JP Morgan issued a "Overweight" rating on 12/10/2025
B of A Securities issued a "Buy" rating on 12/09/2025
Leerink Partners issued a "Outperform" rating on 12/09/2025
Citigroup issued a "Buy" rating on 12/09/2025

To track analyst ratings and price targets for $KYMR, check out Quiver Quantitative's $KYMR forecast page.

$KYMR Price Targets

Multiple analysts have issued price targets for $KYMR recently. We have seen 21 analysts offer price targets for $KYMR in the last 6 months, with a median target of $120.0.

Here are some recent targets:

Faisal Khurshid from Jefferies set a target price of $110.0 on 03/16/2026
David Dai from UBS set a target price of $128.0 on 03/03/2026
Sudan Loganathan from Stephens & Co. set a target price of $100.0 on 03/02/2026
Geoff Meacham from Citigroup set a target price of $120.0 on 03/02/2026
Biren Amin from Piper Sandler set a target price of $140.0 on 02/26/2026
Jeet Mukherjee from BTIG set a target price of $134.0 on 02/26/2026
Etzer Darout from Barclays set a target price of $133.0 on 01/28/2026

Full Release

WATERTOWN, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report first quarter 2026 financial results on April 30, 2026. The Company will host a video conference call and webcast at 8:30 a.m. ET that day.

To join the video call or view the livestreamed webcast, please register via this link , or visit “ News and Events ” in the Investors section of the Company’s website at www.kymeratx.com . A replay of the webcast will be archived and available following the event.

About Kymera Therapeutics
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn .

Investor Contact:
Justine Koenigsberg
[email protected]
857-285-5300

Media Contact:
Matthew Henson
[email protected]
857-285-5300